Overview Request Sample Pages Request Customization Download PDF
You are viewing: US In Vitro Diagnostics Market analysis
Part of: In Vitro Diagnostics Market (Global)

The US In Vitro Diagnostics Market was valued at $25278.2 Million in 2025 and projected to reach to $36923.8 Million by 2030, representing a compound annual growth rate of 7.9%. The US In Vitro Diagnostics Market is poised for sustained growth through 2030, supported by increasing healthcare expenditure, favorable reimbursement policies, and widespread adoption of advanced diagnostic technologies.

US In Vitro Diagnostics Market Trends and Insights

  • The US market benefits from advanced healthcare infrastructure, high diagnostic spending, and strong adoption of innovative testing technologies.
  • Driving this expansion, the US continues to invest heavily in molecular diagnostics, immunoassays, and point-of-care testing solutions that enhance clinical decision-making and patient outcomes. The US In Vitro Diagnostics sector is characterized by robust regulatory frameworks, significant R&D investments, and a competitive landscape dominated by established diagnostic manufacturers.
  • Between 2025 and 2030, the US market will be propelled by increasing prevalence of chronic diseases, aging demographics, and growing demand for personalized medicine.
  • The US healthcare system's emphasis on preventive care and early disease detection further accelerates adoption of advanced diagnostic platforms across hospitals, laboratories, and outpatient settings..

Key Market Statistics

  • CAGR (2025-2030) : 7.9% CAGR
  • Market Size, 2025 : ~USD 25278.2
  • Forecast, 2030 : ~USD 36923.8
  • Country : US

US In Vitro Diagnostics Market Overview

Market Valuation :

The US In Vitro Diagnostics Market is valued at $25,278.2 million in 2025, with strong growth trajectory driven by advanced healthcare infrastructure and high diagnostic spending across the nation.

Robust Growth Rate :

The US market is expanding at a CAGR of 7.9% from 2025 to 2030, outpacing the global average of 7.6%, reflecting accelerated adoption of innovative diagnostic technologies and increased healthcare investments.

Technological Innovation :

The US continues to lead in molecular diagnostics adoption, with significant investments in next-generation sequencing, point-of-care testing, and AI-powered diagnostic solutions driving market expansion.

Projected Market Size :

The market is forecasted to reach $36,923.8 million by 2030, representing a $11.6 billion increase, driven by aging population demographics and rising prevalence of chronic diseases requiring frequent diagnostic testing.

US In Vitro Diagnostics Market Dynamics

  • The market benefits from a mature healthcare system with strong regulatory frameworks and high patient awareness, enabling rapid commercialization of innovative testing solutions.
  • Molecular diagnostics, immunoassays, and point-of-care testing segments are experiencing accelerated demand.
  • The aging US population and rising prevalence of chronic conditions including diabetes, cancer, and cardiovascular diseases are driving increased diagnostic testing volumes.
  • Additionally, the shift toward personalized medicine and preventive healthcare is creating new opportunities for specialized diagnostic applications..

Related Ecosystem

In Vitro Diagnostics

Top Technologies
  • Polymerase Chain Reaction (PCR)
  • Enzyme-Linked Immunosorbent Assay (ELISA)
  • Dna Microarrays
  • Assay Kits
  • Microarrays
Top Companies
  • ROCHE HOLDINGS AG
  • Thermo Fisher Scientific Inc.
  • Danaher Corporation
  • Abbott Laboratories
  • Biomerieux s.a.

    Medical Devices

    Top Technologies
    • Polymerase Chain Reaction (PCR)
    • Magnetic Resonance Imaging (MRI)
    • Disposable Autoinjectors
    • Pulse Oximeters
    • Blood Pressure Monitors
    Top Companies
    • Medtronic plc
    • Stryker Corporation
    • Abbott Laboratories
    • Becton, Dickinson and Company
    • JOHNSON & JOHNSON

      Key Takeaways

      • The US In Vitro Diagnostics Market is valued at $25.3 billion in 2025 and will reach $36.9 billion by 2030, growing at a 7.9% CAGR.
      • The US market is driven by advanced healthcare infrastructure, high diagnostic spending, and strong adoption of molecular and point-of-care testing technologies.
      • Chronic disease prevalence, aging demographics, and demand for personalized medicine are key growth catalysts in the US market through 2030.
      • The US regulatory environment and significant R&D investments support competitive innovation and market expansion in In Vitro Diagnostics.

      US In Vitro Diagnostics Market Report Scope

      Report Metric Details
      Base Year 2025
      Fastest Growing Segment MOLECULAR DIAGNOSTICS (Technology)
      Forecast Period 2025–2030
      Growth Rate CAGR of 7.6% from 2025 to 2030
      Largest Segment REAGENTS & KITS (Product & Service)
      Market Size Base Year 109.29 (2025)
      Revenue Forecast 157.63 (2030)
      Segments Covered Product & Service, Technology, Type, Specimen, Test Type, Application, End User

      US In Vitro Diagnostics Market Report Segmentation

      7 segment dimensions are covered across the global market.

      By Product & Service

      • Data Management Software & Services
      • Data Management Software And Services
      • Instruments
      • Reagents & Kits

      By Technology

      • Blood Gas Analyzers
      • Chromatography & Mass Spectrometry
      • Clinical Chemistry
      • Coagulation & Hemostasis
      • Glucose Monitoring
      • Hematology
      • Immunoassays
      • Microbiology
      • Molecular Diagnostics
      • Urinalysis

      By Type

      • Basic Metabolic Panels
      • Chemiluminescence Immunoassays
      • Dna Microarrays
      • Dna Sequencing & Next-Generation Sequencing (Ngs)
      • Electrolyte Panels
      • Enzyme-Linked Immunosorbent Assays (Elisa)
      • Enzyme-Linked Immunospot Assays (Elispot)
      • Immunofluorescence Assays
      • In Situ Hybridization (Ish)
      • Isothermal Nucleic Acid Amplification Technology (Inaat)
      • Large Reference Laboratories
      • Lipid Profiles
      • Liver Panels
      • Other Immunoassay Technologies
      • Other Molecular Diagnostic Technologies
      • Polymerase Chain Reaction (Pcr)
      • Rapid Tests
      • Renal Profiles
      • Small & Medium-Sized Laboratories
      • Specialty Chemical Tests
      • Thyroid Function Profiles
      • Western Blotting

      By Specimen

      • Blood, Serum, And Plasma Specimens
      • Other Specimens
      • Saliva Specimens
      • Urine Specimens

      By Test Type

      • Laboratory Test
      • Laboratory Tests
      • Point-Of-Care Tests

      By Application

      • Allergy Diagnostics
      • Autoimmune Diseases
      • Blood Group Typing
      • Blood Screening
      • Bone & Mineral Disorders
      • Cardiology
      • Coagulation Testing
      • Drug Monitoring & Testing
      • Endocrinology
      • Genetic Testing
      • Infectious Diseases
      • Oncology
      • Other Applications

      By End User

      • Academic Institutes
      • Blood Banks
      • Clinical Laboratories
      • Home Care Settings
      • Hospitals & Clinics
      • Other End Users
      • Pharmaceutical & Biotechnology Companies

      Target Audience

      • Diagnostic Device Manufacturers : Manufacturers need US market data to assess market opportunity, benchmark against competitors, identify growth segments, and develop product strategies aligned with American healthcare demands and regulatory requirements.
      • Healthcare Investors & PE Firms : Investment professionals require detailed US market sizing, growth projections, and segment analysis to evaluate investment opportunities in diagnostic companies, assess portfolio performance, and identify acquisition targets.
      • Clinical Laboratory Operators : Laboratory networks and independent labs need market intelligence to understand testing volume trends, emerging diagnostic technologies, reimbursement changes, and competitive dynamics affecting their US operations.
      • Healthcare Consultants & Advisors : Consulting firms advising healthcare clients require comprehensive US IVD market data to support strategic recommendations, market entry strategies, and business development initiatives for diagnostic-related services.
      • Pharmaceutical & Biotech Companies : Pharma companies developing companion diagnostics and biotech firms pursuing diagnostic solutions need US market insights to understand adoption rates, reimbursement landscapes, and commercialization pathways.

      Key Companies in the US In Vitro Diagnostics Market

      CompanyHQOwnershipStrongest segments
      CEPHEID INC.United StatesPrivate CompanyKits / Assays (Xpert test cartridges),Instruments (GeneXpert, SmartCycler),Services & Other (service contracts, collaborations),
      AT&SAustriaPublic CompanyKits (including cartridges and consumables manufacturing systems),Instruments (analyzers and device manufacturing systems),Software & digital factory solutions for IVD plants,
      IMMUCOR, INC.United StatesPrivate CompanyTransfusion serology reagents (manual and Capture),Automated serology instruments (NEO, Echo, Capture Workstation),Transplant & molecular assays (HEA/HPA typing, Array Imaging System, BASIS),
      UNILABSSwitzerlandPrivate CompanyKits (consumed in internal labs and managed services),Instruments (installed base within owned and in-house labs),IVD Service Revenue (testing, reporting, and clinical trial support),
      EIKEN CHEMICAL CO., LTD.JapanPublic CompanyKits & Reagents (microbiology, FIT, immunology, serology, urinalysis, clinical chemistry),Instruments & Automated Analyzers,
      DANAHERUnited StatesPublic CompanyKits & Consumables,Instruments,Software & Services,
      ABBOTTUnited StatesPublic CompanyKits & Reagents,Instruments (Core Lab & Hematology),Glucose Monitoring Systems,
      SIEMENS HEALTHINEERS AGGermanyPublic CompanyKits & Reagents,Instruments (Core Lab Analyzers and Hematology Systems),Point-of-Care and Glucose Monitoring,
      THERMO FISHER SCIENTIFIC INC.United StatesPublic CompanyKits & Reagents,Instruments & Analyzers,Services & Others (IVD-related),
      ILLUMINA, INC.United StatesPublic CompanySequencing instruments,Sequencing consumables (reagents, flow cells),Library preparation and targeted/whole-genome kits,
      HOLOGIC, INC.United StatesPrivate CompanyMolecular infectious disease and women’s health assays (Aptima portfolio),Cytology and cervical cancer screening (ThinPrep and related solutions),Other diagnostic assays and instruments (including viral load, SARS-CoV-2, and fetal fibronectin),
      BIO-RAD LABORATORIES, INC.United StatesPublic CompanyKits & Reagents (including QC),Instruments & Systems,Informatics & Software / Services,
      BIOMÉRIEUXFrancePublic CompanyKits & Reagents (including panels, media, CLIA, PCR, AST strips),Instruments & Systems (BACT/ALERT, BIOFIRE platforms, VITEK, VIDAS, CHEMUNEX, TEMPO),Software, Services & Lab Consultancy,
      SYSMEX CORPORATIONJapanPublic CompanyHematology instruments,Hematology reagents and consumables,Coagulation and hemostasis,
      REVVITYUnited StatesPublic CompanyKits & Reagents,Instruments & Analyzers,Software, Subscriptions & Services,
      BECTON, DICKINSON AND COMPANYUnited StatesPublic CompanyKits & Reagents (including microbiology media, TB, infectious disease assays),Instruments & Lab Automation (microbiology, blood culture, identification/susceptibility, flow cytometry),Specimen & Blood Collection Systems,
      AGILENT TECHNOLOGIES, INC.United StatesPublic CompanyInstruments (analyzers, LC/MS, pathology platforms),Kits, reagents, and consumables,Services, software, and informatics (CrossLab, OpenLab),
      QIAGENNetherlandsPublic CompanyKits & Consumables (sample technologies, immune response, oncology, infectious disease assays),Instruments (nucleic acid purification, PCR, digital PCR, integrated sample-to-insight systems),Bioinformatics & SaaS (NGS analysis, interpretation, forensic genealogy services),
      DIASORIN S.P.A.ItalyPublic CompanyImmunoassay Kits (LIAISON menu across infectious disease, endocrinology, oncology),Immunoassay Instruments (LIAISON XL, LIAISON XS),Molecular Diagnostics Kits (Simplexa, LIAISON PLEX assays, xMAP-based IVD),

      CEPHEID INC.

      Cepheid Inc. is a private U.S. company founded in 1996 with 1,700 employees. The company develops molecular diagnostics and point-of-care testing systems.

      AT&S

      AT&S is a publicly traded Austrian company founded in 1978 with 7,000 employees. The company manufactures printed circuit boards and electronics components.

      IMMUCOR, INC.

      Immucor, Inc. is a private U.S. company established in 1982 with 1,125 employees. The company develops immunohematology and transfusion diagnostics products.

      UNILABS

      Unilabs is a private Swiss company established in 1987 with 1,897 employees. The company provides clinical laboratory and diagnostic testing services.

      EIKEN CHEMICAL CO., LTD.

      Eiken Chemical Co., Ltd. is a publicly traded Japanese company founded in 1939 with 696 employees. The company manufactures diagnostic reagents and chemical products.

      DANAHER

      Danaher is a publicly traded U.S. company founded in 1969 with 59,000 employees. The company operates a diversified portfolio of businesses in diagnostics, life sciences, and environmental solutions.

      ABBOTT

      Abbott is a publicly traded U.S. company founded in 1888 with 115,000 employees. The company develops and manufactures pharmaceuticals, diagnostics, medical devices, and nutritional products.

      SIEMENS HEALTHINEERS AG

      Siemens Healthineers AG is a publicly traded German company founded in 1896 with 72,369 employees. The company provides medical imaging, laboratory diagnostics, and healthcare IT solutions.

      THERMO FISHER SCIENTIFIC INC.

      Thermo Fisher Scientific Inc. is a publicly traded U.S. company founded in 1956 with 125,000 employees. The company supplies life sciences, analytical instruments, reagents, and laboratory services globally.

      ILLUMINA, INC.

      Illumina, Inc. is a publicly traded U.S. company founded in 1998 with 8,625 employees. The company develops and manufactures DNA sequencing and genetic analysis systems.

      HOLOGIC, INC.

      Hologic, Inc. is a private U.S. company founded in 1985 with 7,070 employees. The company develops medical devices and diagnostics for women's health and oncology.

      BIO-RAD LABORATORIES, INC.

      Bio-Rad Laboratories, Inc. is a publicly traded U.S. company founded in 1952 with 7,450 employees. The company manufactures clinical diagnostics, life science research products, and quality control systems.

      BIOMÉRIEUX

      bioMérieux is a publicly traded French company founded in 1963 with 14,894 employees. The company develops in vitro diagnostics and microbiology testing solutions.

      SYSMEX CORPORATION

      Sysmex Corporation is a publicly traded Japanese company founded in 1968 with 10,861 employees. The company manufactures hematology, hemostasis, and clinical chemistry diagnostic systems.

      REVVITY

      Revvity is a publicly traded U.S. company founded in 1937 with 11,000 employees. The company provides analytical instruments, software, and services for life sciences and diagnostics.

      BECTON, DICKINSON AND COMPANY

      Becton, Dickinson and Company is a publicly traded U.S. company founded in 1897 with 72,000 employees. The company manufactures medical devices, diagnostics, and laboratory equipment.

      AGILENT TECHNOLOGIES, INC.

      Agilent Technologies, Inc. is a publicly traded U.S. company founded in 1999 with 18,000 employees. The company develops analytical instruments, software, and services for life sciences and diagnostics.

      QIAGEN

      QIAGEN is a publicly traded Dutch company founded in 1984 with 5,500 employees. The company develops molecular diagnostics, sample preparation, and life sciences research products.

      DIASORIN S.P.A.

      DiaSorin S.p.A. is a publicly traded Italian company founded in 1968 with 3,242 employees. The company manufactures immunodiagnostic and molecular diagnostic systems.

      Reasons to Buy this Report

      • Market Size & Growth Data : Access precise valuation of the US IVD market at $25.3B (2025) and 2030 forecasts with detailed CAGR analysis, enabling accurate financial planning and investment decisions for US market entry or expansion.
      • Competitive Intelligence : Understand the US diagnostic landscape, identify key market players, technology trends, and competitive positioning specific to American healthcare systems, regulatory environment, and reimbursement structures.
      • Segment Analysis : Gain insights into high-growth diagnostic segments within the US market including molecular testing, immunoassays, and point-of-care solutions with segment-specific growth rates and market dynamics.
      • Strategic Planning : Leverage US-specific market data to develop targeted go-to-market strategies, identify partnership opportunities, and allocate resources effectively across different diagnostic categories and healthcare settings.
      • Regulatory & Reimbursement Insights : Understand US FDA approval pathways, Medicare/Medicaid reimbursement trends, and healthcare policy impacts on diagnostic adoption, essential for product development and commercialization strategies.

      Frequently asked questions

      What is the current size of the US In Vitro Diagnostics Market in 2025?

      The US In Vitro Diagnostics Market is valued at $25,278.2 million in 2025.

      What is the projected size of the US In Vitro Diagnostics Market by 2030?

      The US In Vitro Diagnostics Market is projected to reach $36,923.8 million by 2030.

      What is the CAGR for the US In Vitro Diagnostics Market from 2025 to 2030?

      The US In Vitro Diagnostics Market is expected to grow at a compound annual growth rate of 7.9% between 2025 and 2030.

      What are the primary drivers of growth in the US In Vitro Diagnostics Market?

      Key growth drivers in the US market include increasing chronic disease prevalence, aging demographics, demand for personalized medicine, and strong adoption of molecular and point-of-care testing technologies.

      Which diagnostic technologies are most prominent in the US market?

      The US market is characterized by strong adoption of molecular diagnostics, immunoassays, and point-of-care testing solutions across hospitals, laboratories, and outpatient settings.

      RESEARCH METHODOLOGY

      This study involved the extensive use of primary and secondary sources. A comprehensive study was conducted using secondary research methods to gather data about the market, its parent market, and its peer markets. The next stage involved conducting primary research to confirm these conclusions and assumptions and sizing with industry experts throughout the value chain. A combination of top-down and bottom-up methods was used to assess the overall market size. The market sizes of segments and subsegments were then estimated using data triangulation techniques and market breakdown.

      Secondary Research

      The secondary research process involves the widespread use of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B Hoovers), white papers, annual reports, investor presentations, SEC filings of companies and publications from government sources [such as National Institutes of Health (NIH), US FDA, US Census Bureau, World Health Organization (WHO), International Trade Administration (ITA), American Association for Clinical Chemistry (AACC), American Diabetes Association (ADA), Association for Molecular Pathology (AMP) and Centers for Medicare and Medicaid Services (CMS) were referred to identify and collect information for the global in vitro diagnostics market study. It was also used to obtain important information about the key players and market classification & segmentation according to industry trends to the bottom-most level and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.

      Primary Research

      In the primary research process, various sources from the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing and sales directors, technology & innovation directors, and related key executives from various key companies and organizations in the in vitro diagnostics market. The primary sources from the demand side include hospitals & clinics, clinical laboratories, blood banks, pharmaceutical and biotechnology companies, and academic institutes. Primary research was conducted to validate the market segmentation, identify key players, and gather insights on key industry trends & key market dynamics.

      A breakdown of the primary respondents is provided below:

      In Vitro Diagnostics Market

      Note 1: C-level primaries include CEOs, CFOs, COOs, and VPs.

      Note 2: Other designations include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.

      Note 3: Tiers are defined based on a company’s total revenue. As of 2023, Tier 1= >USD 10 billion, Tier 2 = USD 1 billion to USD 10 billion, and Tier 3 = < USD 1 billion.

      To know about the assumptions considered for the study, download the pdf brochure

      Market Size Estimation

      For the global market value, annual revenues were calculated based on the revenue mapping of major product manufacturers and OEMs active in the global in vitro diagnostics market. All the major product manufacturers were identified at the global and/or country/regional level. Revenue mapping for the respective business segments/subsegments was done for the major players. The global in vitro diagnostics market was split into various segments and sub-segments based on:

      • List of major players operating in the products market at the regional and/or country level.
      • Product mapping of various in vitro diagnostics manufacturers at the regional and/or country level.
      • Mapping of annual revenue generated by listed major players from in vitro diagnostics (or the nearest reported business unit/product category).
      • Extrapolation of the revenue mapping of the listed major players to derive the global market value of the respective segments/subsegments.
      • Summation of the market value of all segments/subsegments to arrive at the global in vitro diagnostics market.

      The above-mentioned data was consolidated and added with detailed inputs and analysis from MarketsandMarkets and presented in this report.

      Market Size Estimation (Bottom-up Approach & Top-down Approach)

      In Vitro Diagnostics Market

      Data Triangulation

      After arriving at the overall size of the global in vitro diagnostics market through the above-mentioned methodology, this market was split into several segments and subsegments. Where applicable, the data triangulation and market breakdown procedures were employed to complete the overall market engineering process and arrive at the exact market value data for the key segments and subsegments. Examining several macro variables and regional trends from demand- and supply-side players helped triangulate the extrapolated market data.

      Market Definition

      IVD tests are non-invasive tests performed to diagnose, monitor, screen, and assess diseases and health conditions. The term "in vitro," which refers to "in glass," signifies that test tubes or petri dishes are typically used in these tests. These tests are performed artificially on biological samples (blood, urine, and tissues). IVD has a broad scope ranging from sophisticated technologies performed in clinical laboratories to simple and easy-to-use rapid testing kits.

      IVD is used to assess a person's health. This technique is used in precision medicine to determine the suitable course of treatment for particular patients and diagnose and prevent diseases and other medical disorders.

      Stakeholders

      • Transfection products manufacturing companies
      • Pharmaceutical & Biopharmaceutical Companies
      • Chemical Companies
      • Biopharmaceutical Companies
      • Contract Research Organizations (CROs)
      • Contract Development and Manufacturing Organizations (CDMOs)
      • Research Institutes and Universities 
      • Venture Capitalists & Investors
      • Government Associations

      Report Objectives

      • To define, describe, and forecast the in vitro diagnostics (IVD) market based on product & service, technology, specimen, site of testing, application, end user, and region.
      • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and industry-specific challenges).
      • To assess the in vitro diagnostics market with respect to Porter’s Five Forces, regulatory landscape, the value chain, the supply chain, ecosystem analysis, patent protection, pricing assessment, key stakeholders, and buying criteria.
      • To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market.
      • To analyze the opportunities in the IVD market for stakeholders and provide details of the competitive landscape for market leaders.
      • To forecast the size of the IVD market in six primary regions (along with countries)—North America, Europe, the Asia Pacific, Latin America, the Middle East & Africa, and the GCC Countries.
      • To profile the key players operating in the IVD market and comprehensively analyze their core competencies and market shares.
      • To track and analyze competitive developments such as partnerships, agreements, collaborations, acquisitions, expansions, product/technology developments, and product approvals.
      • To benchmark players within the IVD market using the Company Evaluation Quadrant framework, which analyzes market players on various parameters within categories of business strategies, market share, and product offerings.

       

      Get the Full In Vitro Diagnostics Market Report

      Full forecast, segment splits, and company analysis for all In Vitro Diagnostics Market.

      Download Sample Pages Buy Report

      METHODOLOGY

      Need a Tailored Report?

      Customize this report to your needs

      Get 10% FREE Customization

      Customize This Report
      Fact checked
      Cite this Research
      DMCA.com Protection Status